US FDA lifts partial clinical hold on Nurix Therapeutics' NX-2127 Phase 1 trial, enabling enrollment restart.

Nurix Therapeutics announced that the US FDA has lifted the partial clinical hold on its NX-2127 Phase 1 trial, allowing the company to reinitiate enrollment in the study. The hold was placed following the company's communication to the FDA of its intention to transition to an improved manufacturing process. The study aims to evaluate NX-2127 in adults with relapsed/refractory B-cell malignancies.

March 11, 2024
3 Articles

Further Reading